UKALL 2011

• Research type

  Research Study

• Full title

  United Kingdom National Randomised Trial for Children and Young Adults with Acute Lymphoblastic Leukaemia and Lymphoma 2011

• IRAS ID

  79820

• Contact name

  Nicholas Goulden

• Sponsor organisation

  University of Birmingham

• Eudract number

  2010-020924-22

• ISRCTN Number

  ISRCTN64515327

• Duration of Study in the UK

  15 years, 1 months, 0 days

• Research summary

  The UKALL 2011 trial seeks to further refine treatment for children and young adults suffering from acute lymphoblastic leukaemia, which is the commonest cancer of childhood, and the rarer condition; lymphoblastic lymphoma. The aim is to improve survival whilst reducing the burden of therapy for patients, carers and the NHS. Although over 80% of patients with these diagnoses can be cured, there are considerable short term and long term side effects associated with the treatment.

  The UKALL 2011 trial will build on the current best available treatment and will assess whether changes in the way some of the standard anti-leukaemia drugs are given can reduce the side effects associated with treatment. The changes to be tested include:

  - Modification of the scheduling of the steroid drug ‘dexamethasone’ given in the first 4 weeks of treatment

  - Modification of the type of treatment given to prevent the disease returning in the central nervous system

  - Modification of the type of ‘maintenance treatment’ used at the end of treatment

  The trial will be open in 27 UK primary treatment centres for children and young adults. Eligible patients will have acute lymphoblastic leukaemia or lymphoblastic lymphoma and will be aged between 1 and 25 years. Approximately 2640 patients will be recruited over 6 years.

• REC name

  London - Central Research Ethics Committee

• REC reference

  11/LO/1487

• Date of REC Opinion

  2 Dec 2011

• REC opinion

  Further Information Favourable Opinion